Paratek Pharmaceuticals — Investor Presentation (January 2019)
45 slides from Paratek Pharmaceuticals's investor presentation, Jan 4, 2019
Slide 1: Paratek Business Overview & Financial Update January 2019
Paratek Business Overview & Financial Update January 2019 Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories. Exhibit 99.1
Slide 2: Forward-Looking Statements Disclaimer
Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation by, Paratek. The info
Slide 3: Well-Positioned for Future Growth
Well-Positioned for Future Growth Focused on Execution + New Value Creation Near-term Focus New Sources of Value Launch of NUZYRA Prudent Operating Expense Management Non-Dilutive Sources of Capital Life-cycle Opportunities for NUZYRA Bio-Defense Product / Pipeline Expansion
Slide 4: Paratek Investment Highlights
Paratek Investment Highlights NUZYRATM: Potential Blockbuster Antibiotic in Both Hospital and Community Settings Potential Blockbuster Antibiotic with NUZYRA Clear Registration Path: U.S. FDA and EU EMA NUZYRA approved in the United States; October 2018 Filed in the EU in October 2018: Review has be
Slide 5: Experienced Management Team
Experienced Management Team Michael F. Bigham Chairman & CEO Evan Loh, MD President, COO & CMO Led Tygacil Development Doug Pagán Chief Financial Officer Adam Woodrow Chief Commercial Officer Led Tygacil Commercialization William Haskel General Counsel & Corporate Secretary
Slide 6: Paratek Pipeline
Paratek Pipeline Compelling Life-cycle Opportunities Research Preclinical Phase 1 Phase 2 Phase 3 Pre-Registration NDA Filing NDA Approved Commercial Rights SEYSARATM (sarecycline) (U.S.) (ex-U.S.) (Global*) uUTI (IV & Oral) – QIDP ABSSSI (IV & Oral) – QIDP + SPA CABP (IV & Oral) – QIDP + SPA Inflam
Slide 7: Strong Track Record Delivering on Milestones
Strong Track Record Delivering on Milestones Omadacycline Events Timing Results ABSSSI Phase 3 data: IV and oral Q2 2016 Positive Phase 3 data UTI Phase 1b data: PK/PD Q4 2016 Proof-of-principle CABP Phase 3 data: IV and oral Q2 2017 Positive Phase 3 data ABSSSI Phase 3 data: Oral-only Q3 2017 Posit
Slide 8: NUZYRA Commercial Opportunity
NUZYRA Commercial Opportunity Potential Blockbuster Antibiotic in Both Hospital and Community Settings
Slide 9: NUZYRA: A Modernized Tetracycline
NUZYRA: A Modernized Tetracycline Restoring Tetracycline Efficacy with Convenience Attributes 9-Position Modification: Overcomes Ribosomal Protection 7-Position Modification: Overcomes Efflux Pump T1/2 = 16 Hours Clinical and in-vitro activity against select: Gram-positives, Gram-negatives, Atypical
Slide 10: NUZYRA: A Modernized Tetracycline Clinically Meaningful Attributes
NUZYRA: A Modernized Tetracycline Clinically Meaningful Attributes Drive Trial to Adoption Once-daily IV & Oral High & durable clinical efficacy No dosage modifications or monitoring in hepatic or renal impairment No QTc prolongation Low potential for DDIs No cases of C. diff reported in completed c
Slide 11: Significant Unmet Need in CABP
Significant Unmet Need in CABP Important Demography: Together with influenza, CABP is currently the eighth leading cause of death in the U.S.2 All cause 30-day mortality in hospitalized patients exceeds 10%3-5 Hospitalization Rates in CABP are increased in older populations and in populations with c
Slide 12: NUZYRA Opportunities Beyond Current CABP Treatment Options
NUZYRA Opportunities Beyond Current CABP Treatment Options: Addressing Limited Formulations with Safety Concerns Beta-lactam + Macrolide Respiratory Fluoroquinolone Inpatient Rx Non-ICU8 OR NUZYRA as First-Line Therapy: Monotherapy, IV + Oral, when β-lactam/Macrolide or Quinolones are not options ID
Slide 13: Significant Unmet Need in Skin Infections
Significant Unmet Need in Skin Infections Important Demography: Incidence of skin infections requiring hospitalization has substantially increased since the 2000’s1,3 ~ 870,000 admissions, 6.3M office visits, and 3.4M emergency department visits annually4 Underlying co-morbidities including diabetes
Slide 14: NUZYRA Opportunities Beyond Today's Skin Treatment Options
NUZYRA Opportunities Beyond Today’s Skin Treatment Options: Addressing Limited Formulations with Safety Concerns Vancomycin +/- Pip/Tazo Zyvox +/- Pip/Tazo Inpatient Rx OR NUZYRA as First-Line Therapy: Monotherapy, IV + Oral, when Vancomycin/Zyvox +/- Pip/Tazo are not options IDSA SSTI Guideline:1 S
Slide 15: More Oral Options: Unmet Needs NUZYRA Will Address
More Oral Options New Therapies to Overcome Drug Resistance Greater Safety Alternative to Quinolones There are Unmet Needs that NUZYRA Will Address Reduce Hospital Length of Stay Reduce Nursing Time Lack of Different Class Options Reduce Usage of Multi-Drug Combinations NUZYRA Attributes Provide A M
Slide 16: Success Begins in the Hospital with Specialists
Success Begins in the Hospital with Specialists “Go-Home” Strategy to Minimize Hospital Stay IDs ER HCPs Hospitalists Pulmonologists PharmD IDs Allied HCPs Launch and Beyond HOSPITAL Internal Medicine Primary Care Provider NPs, PAs Urgent Care Year 2 and Beyond COMMUNITY
Slide 17: Paving The Path For a Successful Launch
Paving The Path For a Successful Launch Market Access Followed by Commercial Execution for Demand Generation 2018 2019 2020 Oct ‘18 – Jan ‘19 Execution by Select Customer-Facing Team Contract negotiations Pre-orders Qualify key accounts Appointments February ‘19 - Forward Execution by Sales Force &
Slide 18: Focused Launch Targeting Early Adopters
Focused Launch Targeting Early Adopters Expansion to ~80 Representatives by Year End 2019 Physician Segments Guideline and protocol driven Wait for Early Adopters to trial and use Convenient features with IV to oral transition Focused on broad spectrum and efficacy Launch in February 2019 with 40 Sa
Slide 19: Field Force Has Two Simultaneous Objectives
Influencers: IDs PharmD IDs Pharmacy Directors Microbiologists = Field Force Has Two Simultaneous Objectives Institutional Access + Demand Generation Adoption Formulary/Protocols Specialty Access & Buying + Institutional Access Prescribers: IDs ER Hospitalists Pulmonologists Trial & Usage Demand Gen
Slide 20: NUZYRA: As First-line Therapy Targeted Patient Profiles
NUZYRA: As First-line Therapy Targeted Patient Profiles CABP ABSSSI Alternative to fluoroquinolone + β-lactam allergic Prior C. difficile infection Suspected polymicrobial infection + β-lactam / sulfa allergic Renal insufficiency + SSRI
Slide 21: Ensure Seamless Transition from Hospital to Home
Ensure Seamless Transition from Hospital to Home Continuity of Care Providing Access to Oral NUZYRA Continuity of Care Prevent gap in care Sample / Bridge Program (as needed) Reimbursement Support Services Affordability Program 3 Distribution Network IV Formulation National & Regional Distributors O
Slide 22: IV & Oral NUZYRA Packaging
IV & Oral NUZYRA Packaging Easy-to-Use Packs Designed for Patient Convenience
Slide 23: Early Indicators to Track Performance
Early Indicators to Track Performance 1 Covered Lives Institutional Access 3 months Post-Launch 33% of covered lives under contract 12 months Post-Launch 66% of covered lives under contract 12 months Post-Launch 70% of 800 targeted institutions
Slide 24: NUZYRA: U.S. Timeline
MSDs Hired/ Deployed NDA Submitted NDA Accepted Payer Reimbursement and Trade Discussions Finalize Pricing Scientific Exchange Account Teams Hired Publications/News Flow Continues KPI Dashboard Budget Impact Model and Health Economic Analysis and Publications Sales Teams Hired and Trained Regulatory
Slide 25: NUZYRA: Well Positioned for Blockbuster Potential Antibiotic
NUZYRA: Well Positioned for Blockbuster Potential Antibiotic Broad Spectrum Big 3(1) Indications Safety Oral Frequency 2010 Sales(3,4) Levofloxacin 3 Once Daily $3.4B Co-Amoxy clav 3 Twice Daily $2.8B Azithromycin(2) 2 Once Daily $1.8B Ciprofloxacin 3 Twice Daily $1.4B Clarithromycin(2) 2 Twice Dail
Slide 26: Potential $3.9 Billion Addressable U.S. Hospital Market
Potential $3.9 Billion Addressable U.S. Hospital Market by 2028 ABSSSI Opportunity: 1st line treatment (Tx) failure, resistance suspected CABP Opportunity: 1st line Tx failure, resistance suspected UTI Opportunity: 1st line Tx failure (or repeated Tx), ESBL suspected = = X = X = = X = ~12%(1) Fail b
Slide 27: Potential Community Market Opportunity
ABSSSI Opportunity: Initial treatment (Tx) failure, resistance suspected CABP Opportunity: Fluoroquinolone failure, resistance suspected UTI Opportunity: Initial Tx failure (or repeated Tx), ESBL suspected = X = = X = = X = ~5%(1) Fail broad sp + MRSA cov ~6%(2) Fail fluoroquinolone ~3%(3) Fail fluo
Slide 28: NUZYRA Product Guidance and Cash Position
NUYZRA Product Guidance and Cash Position
Slide 29: History Can Repeat Itself
History Can Repeat Itself… Today: Slower starts…But with the Right Attributes, a Strong Finish Recent AB Launches: antibiotics launched since 2010 that have at least 36 months of data - Avycaz, Dalvance, Orbactiv, Sivextro, Teflaro, & Zerbaxa (does not include Dificid or new formulations/line extens
Slide 30: 2019 & 2024 NUZYRA Net Product Revenue Guidance
Paratek: 2019 & 2024 NUZYRA Net Product Revenue Guidance 2019 Guidance Assumptions NUZYRA Net Product Revenues $10 to $13 Million Excludes anticipated revenues from the SEYSARA U.S. royalty stream and potential Department of Defense grant revenues Assumes a U.S. NUZYRA WAC price of $345 per vial for
Slide 31: Strong Balance Sheet
Strong Balance Sheet Key Metrics (unaudited) 12/31/18 balance Total Cash, Cash Equivalents, and Marketable Securities $293.2 million Long-term Debt Obligation $229.0 million Basic Shares Outstanding 32,284,602 Total Potentially Dilutive Securities* 16,709,048 Funding Projected through Q1 2021 * Incl
Slide 32: NUZYRA Efficacy and Safety in ABSSSI and CABP
NUZYRA Efficacy and Safety in ABSSSI and CABP Positive Benefit / Risk Profile
Slide 33: Omadacycline OASIS-1 Study Results
Omadacycline OASIS-1 Study Results Achieved Primary Efficacy Endpoints for Both FDA and EMA EMA Co - Primary Endpoints Delta (95% CI) -0.7 (-6.3, 4.9) Delta (95% CI) +2.5 (-3.2, 8.1) Delta (95% CI) +2.8 (-0.9, 7.1) FDA Primary Endpoint Omadacycline Linezolid
Slide 34: Clinical Success at PTE by Baseline Pathogen (OASIS-1)
*S. anginosus group consists of: S. anginosus, S. intermedius, and S. constellatus. MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; VSE, vancomycin-susceptible enterococci. Clinical Success at PTE by Baseline Pathogen (OASIS-1) Highly Effective
Slide 35: Omadacycline OPTIC Study Results
FDA Primary Endpoint 81.1 88.4 92.5 82.7 85.2 90.5 30 20 10 0 40 50 80 70 60 90 100 Early Clinical Response - ITT Omadacycline Moxifloxacin Delta (95% CI) -1.6 (-7.1, 3.8) Clinical Success at PTE - ITT Clinical Success at PTE - CE-PTE Delta (97.5% CI) +3.3 (-2.7, 9.3) Delta (97.5% CI) +2.0 (-3.2, 7.
Slide 36: Clinical Success at PTE by Baseline Pathogen (OPTIC)
Clinical Success at PTE by Baseline Pathogen* (OPTIC) Highly Effective Across Key Gram (+), Gram (–) & Atypical CABP Pathogens Omadacycline (N=204) Moxifloxacin (N=182) Baseline Pathogen N Clinical Success n (%) N Clinical Success n (%) Atypical Pathogens 118 109 ( 92.4) 106 97 ( 91.5) Mycoplasma pn
Slide 37: Omadacycline OASIS-2 Study Results
EMA Co-Primary Endpoints Delta (95% CI) +5.0 (-0.2, 10.3) Delta (95% CI) +3.3 (-2.2, 9.0) Delta (95% CI) +2.3 (-0.5, 5.8) FDA Primary Endpoint Omadacycline OASIS-2 Study Results Achieved Primary Efficacy Endpoints for Both FDA and EMA
Slide 38: Clinical Success at PTE Baseline Pathogen (OASIS-2)
Clinical Success at PTE Baseline Pathogen (OASIS-2) Highly Effective Across Key Gram (+) Skin Pathogens Omadacycline (n=276) Linezolid (n=287) Baseline Pathogen N Clinical Success n (%) N Clinical Success n (%) Staphylococcus aureus 220 182 (82.7) 233 186 (79.8) MRSA 104 89 (85.6) 107 85 (79.4) MSSA
Slide 39: Omadacycline Safety and Tolerability Profile Established
Selected TEAS Occurring in ≥2% of Patients Receiving Omadacycline in the Pooled Phase 3 CABP and ABSSSI Clinical Trials Omadacycline (N = 1073) Linezolid (N = 689) Moxifloxacin (N = 388) Nausea1 14.9 8.7 5.4 Vomiting1 8.3 3.9 1.5 Diarrhea2 2.4 2.9 8.0 Transaminase Elevations Increased 4.3 4.4 5.2 He
Slide 40: Completed Omadacycline Phase 1b UTI Study Design
Completed Omadacycline Phase 1b UTI Study Design Imminent Need to Replace Quinolones in Cystitis Group 1 (n=10) Dose 200 mg IV Day 1 Dose 300 Oral q24h Days 2-5 Screening (≤ 48 hours prior to randomization) End of Treatment (Day 6) Post Treatment Evaluation Follow-Up Group 2 (n=10) Dose 300 mg Oral
Slide 41: Oral Bioavailability Results in High Omadacycline Concentrations in Urine
Oral Bioavailability Results in High Omadacycline Concentrations in Urine Supports Development for a UTI Indication Day 5 Day 1
Slide 42: Phase 2 UTI Programs Underway
Phase 2 UTI Programs Underway Adaptive Dosing Designs Employed in Cystitis and Acute Pyelonephritis Studies ~200 patients oral omadacycline (up to 450mg) 7 days oral nitrofurantoin 7 days Day 14 (+/- 2d) Post-Therapy Evaluation (PTE) Day 1 Day 7 End of Treatment (EOT) Day 30 - 37 Final Follow-up Cys
Slide 43: NUZYRA IP Protection and Market Exclusivity
NUZYRA IP Protection and Market Exclusivity GAIN Act Ensures 10 Yrs.’ Market Exclusivity and Patent Term Extension protection to at least 2030 Patent Term Extension (PTE) Key Composition of Matter Patent (U.S. 7,553,828) Expires June 2023 2000 2005 2010 2015 2020 2025 2030 ‘828 Patent Issued File ND
Slide 44: Equity Research Analyst Coverage
Equity Research Analyst Coverage Paratek Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Paratek Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or pre
Slide 45: Paratek Investment Highlights
Paratek Investment Highlights NUZYRATM: Potential Blockbuster Antibiotic in Both Hospital and Community Settings Potential Blockbuster Antibiotic with NUZYRA Clear Registration Path: U.S. FDA and EU EMA NUZYRA approved in the United States; October 2018 Filed in the EU in October 2018: Review has be
Paratek Pharmaceuticals — Investor Presentation (January 2019) on 6ix